Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Sexual Fantasies: Threesomes Are Normal, Golden Showers Not So Much
- Ghost Light From Dead Galaxies - A Hubble Halloween
- Mediterranean Diet Linked To Better Kidney Health
- Greenpeace Says Its GMOs Are Better Than Science's GMOs, Still Hates Golden Rice
- US Wildlife Bans On GMOs And Neonics Lack Transparency And Scientific Rationale
- Coulrophobia: Are Clowns Scary? Ha Ha Aaaargh
- Homo Floresiensis: Hobbit Species Continues To Provoke Questions About Human Evolution
- "Twelve years in a major urban public school system, and I couldn't once bring myself to eat a school..."
- "Hardly a day goes by without some creative new take on the eternal Evil White Man meme. Without..."
- "There would be no controversy if it were all balloons and ponies stories like that. But I hope..."
- "Let's talk about this disaster: I lost a course at the university where I work and became ineligible..."
- "Partisan nastiness doesn't advance dialogue. We are all in this together. You asked for solutions..."
- Battle of Britain: NGOs and scientists clash over proposal to loosen EU GMO restrictions
- Genetically modified clean energy from bacteria
- Designer babies: You can screen for cystic fibrosis but intelligence is a ways off
- Science as profane: What superstition of 1752 and 2014 share in common
- What’s so “natural” about “natural crop breeding”?
- Worried you have cancer? Take a Google pill!
- Report examines health care challenges for pregnant women enrolled in covered California
- NYU research: Majority of high school seniors favor more liberal marijuana policies
- ESA Frontiers November preview
- Sexual fantasies: Are you normal?
- Synthetic lethality offers a new approach to kill tumor cells, explains Moffitt researcher